Lv1
80 积分 2023-03-10 加入
Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective
12天前
已完结
Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application
13天前
已完结
Efficacy of upadacitinib in treating a paediatric case of refractory Takayasu arteritis
18天前
已完结
Efgartigimod as a novel FcRn inhibitor for autoimmune disease
19天前
已完结
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
22天前
已完结
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
23天前
已完结
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
27天前
已完结
Management of lymphatic malformations in children
1个月前
已完结
An update on drug repurposing in Parkinson’s disease: Preclinical and clinical considerations
1个月前
已完结
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
1个月前
已完结
皖公网安备34019202002308
